Fluconazole for the treatment of onychomycosis: an update

Gupta, Aditya K.; Scher, Richard K.; Rich, Phoebe

doi:10.1046/j.1365-4632.1998.00564.x

Cited by 17 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it was found that the in vitro antifungal activity of voriconazole and efinaconazole against all Candida isolates was superior to those of other drugs, which is in line with previously published data on Candida isolates . The majority of the patients with onychomycosis caused by Candida species are commonly treated by means of the itraconazole pulse therapy; however, fluconazole is also administered as the second line drug . In our study, 67% of the Candida isolates were susceptible to fluconazole; therefore, this may be a promising alternative for the treatment of onychomycosis caused by Candida species.…”

Section: Discussionsupporting

confidence: 90%

Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species)

Haghani

Shams-Ghahfarokhi

Dalimi

et al. 2018

Mycoses

View full text Add to dashboard Cite

Summary Onychomycosis is a common nail problem, accounting for up to 50% of all nail diseases. The aim of the present study was to determine the species distribution based on the restriction fragment length polymorphism and susceptibility patterns of the causative agents of onychomycosis. This cross‐sectional study was conducted on nail samples collected from 257 patients suspected of onychomycosis during 14 months. Fungal isolates were identified by polymerase chain reaction‐restriction fragment length polymorphisms (PCR‐RFLP) with the enzymes Msp I, Mva I, Alw I and sequencing. According to the results, out of the 257 patients participating in the study, onychomycosis was diagnosed in 180 (70.03%) cases, among which 51.1% were caused by non‐dermatophyte moulds (NDMs), 35% by yeast and 10.6% by dermatophytes. Numerous cryptic species recovered from onychomycosis for the first time. In the majority of cases, novel triazoles and imidazoles (ie, efinaconazole, luliconazole and lanoconazole) showed potent activity in comparison with other antifungal agents. The minimum inhibitory concentration (MIC) of luliconazole and lanoconazole ranged within 0.001 to >1 μg/mL and their geometric mean MICs were 0.0154 and 0.0309 μg/mL against all isolates, respectively. It seems that obtained data will be useful to improve the knowledge of researchers, clinicians and dermatologists about onychomycosis distribution, species diversity and adoption of appropriate treatment.

show abstract

Section: Discussionsupporting

confidence: 90%

Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species)

Haghani

Shams-Ghahfarokhi

Dalimi

et al. 2018

Mycoses

View full text Add to dashboard Cite

show abstract

“…10 Of the newer drugs, terbinafine (Lamisil) and itraconazole (Spora-nox) are the most widely used, with fluconazole (Diflucan) rapidly gaining acceptance. These medications share characteristics that enhance their effectiveness: prompt penetration of the nail and nail bed, 3,11 persistence in the nail for months after discontinuation of therapy 12,13 and generally good safety profiles. Published studies measuring "mycologic cure" (negative KOH preparation or negative cul-…”

Section: Treatmentmentioning

confidence: 99%

“…[15][16][17] Fluconazole is not currently labeled by the FDA for the treatment of onychomycosis, but early efficacy data are promising. 13,27,28 Attention has focused on once-weekly dosing (450 mg), taking advantage of the drug's pharmacokinetics to reduce treatment costs, decrease rates of adverse effects and potentially improve compliance.…”

Section: Fluconazolementioning

confidence: 99%

Treating Onychomycosis

Rodgers

Bassler²

2014

J Turk Acad Dermatol

View full text Add to dashboard Cite

show abstract

“…The pharmacokinetic profile of fluconazole is that the triazole is detected in both skin and nails within hours of administration. 105–111 Following discontinuation of fluconazole, 150 mg and 300 mg once weekly given for a maximum of 12 months to treat dermatophyte onychomycosis of the toenails, drug levels in the nail plate have been reported to decrease with a half‐life of 2.5 and 2.4 months, respectively. In most subjects, measurable fluconazole concentrations may still be present in toenails for 6 months 109 and in fingernails for 4 months following discontinuation of therapy.…”

Section: Fluconazolementioning

confidence: 99%